Long‐term efficacy and safety of tacalcitol ointment in patients with chronic plaque psoriasis

Summary Background  As psoriasis patients often require continuous treatment optimal therapy has to provide efficacy and a good safety profile over the long term.

[1]  P. Harrison.  Topical tacalcitol treatment for psoriasis. , 2000, Hospital Medicine.

[2]  H. DeLuca,et al.  Current understanding of the molecular actions of vitamin D. , 1998, Physiological reviews.

[3]  P. C. van de Kerkhof.  An Update on Vitamin D3 Analogues in the Treatment of Psoriasis , 1998, Skin Pharmacology and Physiology.

[4]  S. Iqbalb,et al.  The effects of topical calcipotriol on systemic calcium homeostasis in patients with chronic plaque psoriasis , 1997 .

[5]  N. Veien,et al.  Once daily treatment of psoriasis with tacalcitol compared with twice daily treatment with calcipotriol. A double‐blind trial , 1997, The British journal of dermatology.

[6]  T. Luger,et al.  Long-term efficacy and safety of once daily treatment of chronic plaque psoriasis with tacalcitol ointment , 1997 .

[7]  K. Kragballe,et al.  Vitamin D3 analogues. , 1997, Clinics in dermatology.

[8]  T. Luger,et al.  Tacalcitol ointment in the treatment of psoriasis vulgaris:a multicentre, placebo‐controlled, double‐blind study on efficacy and safety , 1996, The British journal of dermatology.

[9]  K. Goa,et al.  Calcipotriol: A Review of its Pharmacological Properties and Therapeutic Efficacy in the Management of Psoriasis , 1996 .

[10]  C. Scarpa.  Tacalcitol ointment is an efficacious and well tolerated treatment for psoriasis , 1996 .

[11]  P. Hutchinson,et al.  High dose topical calcipotriol consistently reduces serum parathyroid hormone levels , 1994, Clinical endocrinology.

[12]  J. Bourke,et al.  Urine calcium excretion during treatment of psoriasis with topical calcipotriol , 1993, The British journal of dermatology.

[13]  K. Matsumoto,et al.  Effect of 1,24R‐dihydroxyvitamin D3 on the Growth of Human Keratinocytes , 1990, Journal of dermatology (Print).

[14]  W. Cunliffe,et al.  A double‐blind, placebo‐controlled trial of topical 1,25‐dihydroxycholecalciferol in psoriasis , 1989, The British journal of dermatology.

[15]  J. Berth-Jones,et al.  The emergence of vitamin D as a first-line treatment for psoriasis , 1998 .

[16]  P. Kerkhof.  An Update on Vitamin D3 Analogues in the Treatment of Psoriasis , 1998 .

[17]  H. Gollnick,et al.  Current experience with tacalcitol ointment in the treatment of psoriasis. , 1998, Current medical research and opinion.

[18]  P. C. van de Kerkhof,et al.  A long-term assessment of the safety and tolerability of calcitriol ointment in the treatment of chronic plaque psoriasis , 1996 .

[19]  O. Baadsgaard,et al.  Optimal concentration of tacalcitol in once-daily treatment of psoriasis , 1995 .

[20]  W. Cunliffe,et al.  Long-term use of topical calcipotriol in chronic plaque psoriasis. , 1994, Dermatology.

[21]  S. Nishiyama,et al.  Topical 1α, 24(R)-dihydroxyvitamin D3 for the treatment of psoriasis. Review of the literature , 1993 .

[22]  Anthony W. Norman,et al.  Vitamin D : gene regulation, structure-function analysis, and clinical application : proceedings of the Eighth Workshop on Vitamin D, Paris, France, July 5-10, 1991 , 1991 .

[23]  J. Dry,et al.  Vitamin D in dermatology. , 1990 .

[24]  T Fredriksson,et al.  Severe psoriasis--oral therapy with a new retinoid. , 1978, Dermatologica.

[25]  J. Krafka.  A simple treatment for psoriasis. , 1936 .